ADELAIDE: Mayne Pharma Group Limited (ASX: MYX) has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022.
This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.
Mr O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers.
He was previously the Chairman and CEO
of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products.
He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences.
Mr O’Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies.
At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands.
Mayne Pharma’s Chair Mr Frank Condella said, “The Board is excited to appoint someone of Shawn’s calibre to lead Mayne Pharma. Shawn has been a highly effective global leader and his experience in sales and marketing, strategic planning, business development, product development and commercialisation will complement our senior leadership team.
He has a proven ability to turn around organisations, lead large and diverse teams and deliver growth within both public and private companies.
Shawn is an ideal choice to lead our next phase of growth and pursue Mayne Pharma’s strategic agenda both organically and through strategic expansion opportunities.”
Mr Shawn Patrick O’Brien said, “I am delighted to be part of Mayne Pharma’s next phase of growth and creating value for all its stakeholders. Mayne Pharma has a compelling mix of potential near-term opportunities for value creation including NEXTSTELLIS® oral contraceptive, further
expansion of the dermatology and women’s health portfolio and building the International CDMO and specialty pharma business. I would like to thank the Board for their trust and confidence in allowing me to lead Mayne Pharma.”
Mr Richards will cease to be CEO and Managing Director and a member of the Board of Directors of Mayne Pharma with effect from 1 October 2022. Mr Richards will remain an employee until 30 November to help ensure a well-managed transition to the new CEO.
This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.
Mr O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers.
He was previously the Chairman and CEO
of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products.
He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences.
Mr O’Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies.
At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands.
Mayne Pharma’s Chair Mr Frank Condella said, “The Board is excited to appoint someone of Shawn’s calibre to lead Mayne Pharma. Shawn has been a highly effective global leader and his experience in sales and marketing, strategic planning, business development, product development and commercialisation will complement our senior leadership team.
He has a proven ability to turn around organisations, lead large and diverse teams and deliver growth within both public and private companies.
Shawn is an ideal choice to lead our next phase of growth and pursue Mayne Pharma’s strategic agenda both organically and through strategic expansion opportunities.”
Mr Shawn Patrick O’Brien said, “I am delighted to be part of Mayne Pharma’s next phase of growth and creating value for all its stakeholders. Mayne Pharma has a compelling mix of potential near-term opportunities for value creation including NEXTSTELLIS® oral contraceptive, further
expansion of the dermatology and women’s health portfolio and building the International CDMO and specialty pharma business. I would like to thank the Board for their trust and confidence in allowing me to lead Mayne Pharma.”
Mr Richards will cease to be CEO and Managing Director and a member of the Board of Directors of Mayne Pharma with effect from 1 October 2022. Mr Richards will remain an employee until 30 November to help ensure a well-managed transition to the new CEO.
Shawn Patrick O’Brien, appointed Chief Executive Officer, Mayne Pharma Group,
He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences.
Mr O’Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies.
At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands.
Mayne Pharma’s Chair Mr Frank Condella said, “The Board is excited to appoint someone of Shawn’s calibre to lead Mayne Pharma. Shawn has been a highly effective global leader and his experience in sales and marketing, strategic planning, business development, product development and commercialisation will complement our senior leadership team.
He has a proven ability to turn around organisations, lead large and diverse teams and deliver growth within both public and private companies.
Shawn is an ideal choice to lead our next phase of growth and pursue Mayne Pharma’s strategic agenda both organically and through strategic expansion opportunities.”
Mr Shawn Patrick O’Brien said, “I am delighted to be part of Mayne Pharma’s next phase of growth and creating value for all its stakeholders. Mayne Pharma has a compelling mix of potential near-term opportunities for value creation including NEXTSTELLIS® oral contraceptive, further
expansion of the dermatology and women’s health portfolio and building the International CDMO and specialty pharma business. I would like to thank the Board for their trust and confidence in allowing me to lead Mayne Pharma.”
Mr Richards will cease to be CEO and Managing Director and a member of the Board of Directors of Mayne Pharma with effect from 1 October 2022. Mr Richards will remain an employee until 30 November to help ensure a well-managed transition to the new CEO.